Pomerantz Law Firm Investigates Iovance Biotherapeutics Following Clinical Trial Data Discrepancy
Pomerantz LLP has launched an investigation into Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) regarding potential securities fraud or unlawful business practices. The probe follows a significant discrepancy in how the company communicated results from its Phase 2 IOV-LUN-202 clinical trial for lifileucel, an investigational therapy for non-squamous non-small cell lung cancer. While Iovance previously described the trial data as "Positive," subsequent reporting clarified that the results were merely "Consistent with Previously Reported Results." Specifically, one subgroup showed a response rate of 11.4%, which is lower than the 12.8% standard response rate for patients receiving typical treatments. This shift in narrative led to a sharp market reaction, with shares dropping over 35% on October 29, 2026.
Tickers: $IOVA
Topics: class action lawsuit clinical trial data discrepancy securities fraud investigation stock price decline
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates Iovance Biotherapeutics Following Clinical Trial Data Discrepancy (2 articles)